(Also see "China Investment Roundup: Active Deal-Making In Precision Medicine" - Scrip, 19 December, 2017.)

Winter is coming, yet China’s financial market is still hot for healthcare companies looking at a prosperous period of investment before the year ends. Capital investments from Chinese investors dramatically increased in November, particularly in the precision medicines segment. Although Chinese Creat Group’s expected record-breaking outbound pharmaceutical acquisition deal worth $1.5bn failed to gain US approval, cross-border M&A remained active.

(Also see "Futurology: Are Mega Mergers A Thing Of The Past?" - Scrip, 19 December, 2017.)

Bolt-ons or big-ticket buys? As another year passes without a big pharma mega merger despite industry giants sitting on large cash piles, we consider whether 2018 will bring major upheaval in the industry landscape, and where M&A will be most likely to take place.

Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony

More from Deals

More from Business